Clinical trial · Observational
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms. As more patients require ongoing treatment and long-term care, the demand for haematology services is increasing. Home-based treatment is expected to play an increasingly important role in the future. It can support more patient-centred care, help patients maintain their everyday lives, improve quality of life, and reduce pressure on hospitals. Despite these benefits, some patients are either not eligible for home-based treatment or choose to decline it. The reasons for this are not yet well understood. This study combines quantitative data-such as medical information, sociodemographic characteristics, and questionnaire responses about quality of life and health literacy-with qualitative interviews involving patients, relatives, and healthcare professionals. The aim is to identify barriers and differences between patients, and to better understand why some patients opt out of or are unable to participate in home-based treatment. The findings will help support the development of more inclusive and patient-centred care models, ensure more equal access to home-based treatment, and improve support for socially vulnerable patients. The results will be shared with patients and families through patient organisations, with hospitals through the Treat@Home programme, and at national and international conferences.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma | — | UNRESOLVED | — |
| Multiple Myeloma Progression | — | UNRESOLVED | — |
| Multiple Myeloma Refractory | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Patients enrolled in a Treat@Home study
- description
- Patients who are enrolled in one of the two Treat@Home studies will be invited to participate
- label
- Patients declining enrollment in a Treat@Home study
- description
- Patients who are invited in one of the two Treat@Home studies but decline this invitation will be invited to participate
- label
- Patients deemed not eligible for enrollment in a Treat@Home study
- description
- Patients deemed not eligible for enrollment in one of the two Treat@Home studies will be invited for enrollment
Primary outcomes (3)
- measure
- Perceptions - patient
- timeFrame
- Day 1
- description
- Semi-structured interviews with patients at inclusion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * \>=18 years old * diagnosed Multiple Myeloma or acute leukemia, and recieving treatment with either Daratumumab or Cytarabine. Exclusion Criteria: \- Dementia, psychotic disorders, or other cognitive impairments limiting participation.
References
Publications (0)
Data not yet available